There are two FDA-approved drugs targeting BRAFV600E/K, vemurafenib (PLX4032) and dabrafenib, but their efficacy against melanoma is not fully satisfactory, even if they are used in combination with inhibitors of the downstream kinases MEK1/2, trametinib, and cobimetinib [108]. This evidence concerns the gene MAP2K1 and melanoma.